Search PubMed⌕ Search

Biomedical subjects

J Rivier

Publications and source records attributed to J Rivier.

At least 343 records · Page 19Linked to original sources
PubMed1981

Arginine vasopressin and a vasopressin antagonist peptide: opposite effects on extinction of active avoidance in rats.

Systemic injection or arginine vasopressin (AVP) (1 micrograms/rat) significantly prolonged extinction of a pole-jump, active avoidance response in rats; lateral ventricular injection of 1000-fold less AVP (1 ng/rat) produced similar results. A new AVP analogue, [1-deaminopenicillamine-2-(O-methyl)tyrosine]arginine vasopressin (dPTyr-(Me)AVP), is known to antagonize behavioral and vascular effects of exogenous AVP at molar ratios of 5 : 1. At a dose of 100 micrograms/rat (subcutaneously) dPTyr-(Me)AVP produces, by itself, a behavioral effect opposite to that of exogenous AVP, namely a facilitation of extinction. Injections of dPTyr-(Me)AVP into the lateral ventricle were ineffective except at a dose of 10 micrograms/rat. These results confirm previous reports of the effect of vasopressin on delaying extinction of avoidance behavior, but suggest a site of action distant from the lateral ventricle.

Animals↗
PubMed1981

Is somatostatin or a somatostatin-like peptide involved in central nervous system control of gastric secretion?

Intracisternal injection of octapeptide analogs of somatostatin (SS), Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys (des-AA1,2,4,5,12,13-[D-Trp8]SS (ODT8-SS)) and Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Cys, increased the volume and the acid output of gastric secretion in rats. ODT8-SS given intravenously did not affect basal gastric secretion. The gastrosecretory effect of ODT8-SS, administered intracisternally is dose-dependent (0.01-1 micrograms), long acting, reversible, specific, and abolished by vagotomy, or systemic injection of atropine or SS. SS (5-10 micrograms) or [D-Trp8]SS (1 microgram) had no effect on gastric secretion when given intracisternally. These results demonstrate that some octapeptide SS analogs, unlike SS or other SS analogs, have the capability to act in the brain to induce a vagal dependent stimulation of gastric secretion.

Animals↗
PubMed1981

Brain regulation of gastric acid secretion in rats by neurogastrointestinal peptides.

Brain alteration of catecholaminergic, serotoninergic, dopaminergic, gabaergic and cholinergic pathways by intracisternal injection of agonists, antagonists or specific neurotoxic drugs did not significantly affect gastric acid secretion in 2 hr pylorus-ligated rats. In contrast, several neuropeptides were found to be very potent in influencing gastric secretion when administered intracisternally but not when given intravenously. Bombesin-like peptides, opioid peptides and arginine vasopressin acted within the brain to inhibit gastric acid secretion through yet unknown neurohumoral pathways, whereas TRH and some somatostatin analogs elicited brain stimulation of gastric acid output through vagal-dependent mechanisms. These observations have led to the concept that some specific neuropeptides may be important chemical messengers involved in physiologic brain processes regulating gastric acid secretion, and appear as new chemical probes to further investigate the brain-gut relationship.

Animals↗
PubMed1981

The effect of LHRH antagonist analogs and an antibody to LHRH on mating behavior in female rats.

The action of two antagonist analogs and an antibody to luteinizing hormone-releasing hormone (LHRH) on sexual receptivity was studied in avariectomized, estrogen-progesterone primed female rats. Small amounts of each LHRH substance or saline was infused through a cannula positioned in either the third ventricle or arcuate-ventromedial (ARC-VMH) area of the hypothalamus. Infusions were carried out at the time of progesterone priming, which was 42 hrs post-estrogen treatment, and sexual receptivity, as denoted by the lordosis-to-mount ratio, was measured six hrs later. One antagonist analog, [D-pGlu1, D-Phe2, D-Trp3,6]-LHRH[1], had little or no effect on sexual receptivity when tested in either site. Similarly, an antibody to LHRH, tested only in the ARC-VMH, had no observable effect on lordotic behavior. However, the second and the most potent antagonist analog, [Ac-dehydro-Pro1, pCl-D-Phe2, D-Trp3,6]-LHRH[2], produced a marked and significant decrement in lordotic behavior when infused into either the third ventricle or ARC-VMH. These results suggest that this potent and long-acting, competitive antagonist analog of LHRH prevented endogenous LHRH from exerting its normal role in the induction of sexual receptivity and provide evidence to support the contention that the role of LHRH in mediating receptivity in the female rat is physiologically relevant.

Animals↗
PubMed1981

Primary structure of corticotropin-releasing factor from ovine hypothalamus.

Sequence analysis was performed of an ovine hypothalamic 41-residue polypeptide that had been postulated to be a putative corticotropin-releasing factor (CRF) because of its high intrinsic corticotropin releasing activity. The NH2-terminal 39 residues of CRF were determined by Edman degradation of 0.6-3.5 nmol of peptide in a Wittmann-Liebold modified Beckman 890C spinning cup sequencer with reverse-phase high-pressure liquid chromatography for the identification of amino acid phenylthiohydantoins (direct micro-sequence analysis). Evidence for residue 40 (isoleucine) was provided by direct micro-sequence analysis of 2.0 nmol of acetylated CRF selectively cleaved at its arginine residues by trypsin prior to analysis. The thermolytic COOH-terminal fragment isoleucyl-alanineamide was characterized as its dansyl derivative. Based on the analytical data, the following primary structure is proposed for ovine hypothalamic CRF: H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Leu-Asp -Ile-Ala-NH2. In agreement with this proposal, the synthetic replicate of CRF is highly potent in stimulating secretion of both corticotropin and beta-endorphin-like immunoactivities.

Adrenocorticotropic Hormone↗
PubMed1981

Antireproductive effects of a potent GnRH antagonist in the female rat.

The administration of the potent gonadotropin-releasing hormone antagonist [Ac-dehydro-Pro1,pCl-D-Phe2,D-Trp3,6,N alpha MeLeu7]GnRH (Antag) to female rats results in disruption of the estrous cycle and gestation. Daily doses of 200 microgram Antag are completely effective in blocking regular cycles, which resume 6-9 days after cessation of treatment. When administered to mated female rats, Antag seems to be less effective in terminating pregnancy during the earlier (1-7 days) than later (7-12 days) days of gestation. This may reflect the inability of Antag to lower the secretion of PRL (the luteotropic hormone of early pregnancy) as compared to the Antag-induced inhibition of LH production (the luteotropic hormone of midpregnancy). As a result, administration of Antag 7-12 days after mating is accompanied by a decrease in plasma progesterone levels incompatible with the survival of the embryos. These data provide further evidence that the neutralization of the function of endogenous gonadotropin-releasing hormone is deleterious to reproductive integrity.

Animals↗
PubMed1981

Effect of a potent GnRH antagonist and testosterone propionate on mating behavior and fertility in the male rat.

Daily treatment with 1 mg of the GnRH antagonist [Ac-delta 3-Pro1,pC1-D-Phe2,D-Trp3,6,N alpha MeLeu7]-GnRH abolished mating behavior and disrupted spermatogenesis in male rats within 2 weeks. This was accompanied by a sharp decrease in plasma testosterone (T) levels as well as sexual organ weights while body weight remained normal. Following cessation of treatment, T levels returned to control values within 5 days, while sexual organ weights were still slightly depressed after 6 weeks. In rats having been treated for either 2 weeks or 4 months, mating behavior and fertility were restored between the 4th and 8th week after the last injection. Antagonist-treated animals who concomitantly received high doses of exogenous testosterone were sexually active as well as fertile, while lower doses of testosterone maintained sexual activity but not fertility. These data indicate that GnRH antagonists may be used to control male fertility.

Animals↗
PubMed1981

Somatostatin-28: selective action on the pancreatic beta-cell and brain.

Somatostatin-28 (SS-28) is 380 times as potent as somatostatin-14 (SS-14) to inhibit acutely insulin secretion induced by arginine in vivo; SS-28 is only 3 times as potent as SS-14 to inhibit glucagon secretion induced by arginine. D-Trp substitution in position 28 of SS-28 increase potency to 2600 times that of SS-14 for inhibition of arginine induced insulin secretion. SS-28 in 10 and [D-Trp22]-SS-28 is 100 times as potent as SS-14 to act within the central nervous system to inhibit bombesin induced hyperglycemia. SS-28 compared to SS-14 shows pancreatic beta-cell and brain selectivity of action.

Animals↗
PubMed1981

Characterization of human anti-luteinizing hormone-releasing hormone (LRH) antibodies in the serum of a patient with isolated gonadotropin deficiency treated with synthetic LRH.

In this report we describe the characteristics of human anti-LRH antibodies detected in the serum of a male patient with isolated gonadotropin deficiency. He had received 90 days of therapy with LRH (1 mg, sc, three times daily) and was then placed on three cycles of intermittent therapy (3 weeks of LRH daily, followed by hCG every 3 days for 15 days). At the start of the fourth cycle of therapy with LRH, he developed urticaria at the site of injection, at sites of previous LRH injections, and at distant sites. Upon direct skin testing, the patient reacted positively to 0.02 ng LRH intradermally. A positive intradermal reaction was induced in a normal adult male by preparing his skin with 0.1 ml of the patient's serum and, 24 h later, injecting 0.2 microgram LRH at that site. A binding factor for LRH was detected in the patient's serum by incubation with [125I]LRH. The serum bound 33% of tracer compared to 6% in control serum. We have detected both immunoglobulin G and immunoglobulin E antibodies against LRH in the patient's serum. We have compared displacement of tracer by synthetic LRH with displacement achieved by a series of analogs. Displacements of tracer by LRH, [Lys8]LRH, [D-Trp6,Pro9-NEt]LRH, [des-Gly10]LRH, and [Phe2]LRH were similar, whereas the potencies of Ac-LRH5-10 and AcLRH2-10 were 0.1% or less.

Adult↗
PubMed1981

Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty.

A two year girl with idiopathic true precocious puberty was treated with a long-acting LHRH agonist, D-Trp6-Pro9-NEt-LHRH (LHRHa). Prior to therapy, the patient demonstrated pulsatile gonadotropin secretion during both night and day, a pubertal response to exogenous LHRH, and an elevated plasma estradiol level. After eight weeks of therapy (4 microgram/kg daily), a mean gonadotropin levels fell to the prepubertal range, there was no evidence of pulsatile discharge of gonadotropins nor any response to exogenous LHRH, and plasma estradiol levels became undetectable. No adverse drug reactions were encountered and all effects of therapy were reversed following cessation of treatment for two months. LHRH analogs may offer a new approach to the therapy of idiopathic precocious puberty and merit further study.

Child, Preschool↗
PubMed1981

The effect of somatostatin analogs on secretion of growth, pancreatic, and gastrointestinal hormones in man.

The potency and specificity of somatostatin (SS) and four of its analogs were compared in seven patients with pancreatic endocrine tumors. The analogs tested were [D-Trp8]-SS, [D-Trp8, D-Cys14]-SS, Des-Asn5-[D-Trp8, D-Ser13]-SS, and Des (AA)1,2,4,5,12,13, [D-Trp8]-SS, and they did not show selective effects on the suppression of basal concentrations of GH, insulin, glucagon, pancreatic polypeptide, gastrin, gastric inhibitory peptide, motilin, enteroglucagon, or neurotensin. The observation that the potency of these analogs is similar to that of the parent molecule throws considerable light on the structure/activity relationship of the somatostatin molecule. Des-AA1,2,4,5,12,13, [D-Trp8]-Ss has been reported to have a prolonged action when administered sc. When administered iv, however, this octapeptide analog ws not long acting, suggesting that the prolonged action seen in the previous study was a result of delayed uptake from the injection site. An increment in plasma SS concentrations of 19 +/- 3 pmol/liter suppressed basal concentrations of GH, insulin, glucagon, and several gastrointestinal hormones by more than 50%, suggesting that even small changes in plasma SS levels may be physiologically important.

Adult↗
PubMed1981

Central nervous system inhibition of gastric secretion in the rat by gastrin-releasing peptide, a mammalian bombesin.

Gastrin-releasing peptide is a 27-amino acid peptide recently isolated from porcine gut. It shares a common C-terminal decapeptide homology with bombesin (except for a His/Gln interchange at residue 8 from C-terminus). Synthetic porcine gastrin-releasing peptide was shown to release gastrin 5 min after intravenous injection in rats. Given intracisternally (0.3--3 microgram), but not intravenously (1--10 micrograms), gastrin-releasing peptide caused a dose-dependent reduction in gastric secretion (volume and acidity) and elevation in plasma gastrin levels measured 2 h after peptide injection and pylorus ligation in rats. Gastrin-releasing peptide given intracisternally had long acting, reversible, and specific inhibitory effects. Gastrin-releasing peptide blocked the secretion of acid evoked by 2-deoxy-D-glucose or TRH given intracisternally or by histamine given subcutaneously. The acetylated C-terminal octapeptide fragment of gastrin-releasing peptide inhibited gastric acid secretion as effectively as gastrin-releasing peptide. Acetylated C-terminal heptapeptide did not. These results demonstrated that gastrin-releasing peptide has the capability to act in the brain to inhibit basal and stimulated gastric secretion and its antisecretory effect does not depend on a decrease in gastrin release. The presence of bombesin immunoactivity in rat brain and its ability to act through the brain to inhibit gastric acid secretion suggest that bombesinlike peptides may be chemical messengers involved in central nervous regulation of gastric secretion.

Animals↗
PubMed1980

Antireproductive effects of a potent gonadotropin-releasing hormone antagonist in the male rat.

Administration of a potent antagonist of gondadotropin-releasing hormone (GnRH) antagonist [Ac-dehydro-Pro1, pCl-D-Phe2, D-Trp3,6]-N alpha-MeLeu7-GnRH to adult male rats for 2 weeks resulted in decreased testosterone production and sexual organ weights and in disrupted spermatogenesis. The results demonstrate the essential role of gonadotropin-releasing hormone in the maintenance of reproductive functions and have implications for the regulation of male fertility.

Animals↗